- In Q2, net sales increased 8.8% year-over-year to $79.4 million; Med Tech sales grew 13% to $35.7 million
- At $43.8 million, Med Device sales were up 5.6% in Q2, compared to $41.3 million in the prior-year period
- AngioDynamics incurred a net loss of $6.4 million or $0.15 per share in Q2, vs. a loss of $10.7 million or $0.26 per share last year
- Excluding special items, on an adjusted basis, the company reported break-even for the quarter, compared to a loss of $0.04 per share in Q2 2025
- Adjusted EBITDA, excluding one-off items, was $5.9 million, compared to $3.1 million in the second quarter of 2025
- The management said it continues to expect to be cash flow positive in the full fiscal year 2026
- The company raised its FY26 net sales guidance to $312-314 million from the earlier outlook of $308-313 million
- It expects a loss per share in the range of $0.33-0.23 for FY26, on an adjusted basis, which is unchanged from the prior guidance
Market News
Earnings Summary: AngioDynamics (ANGO) Q2 FY26 sales increase 8.8%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026. In Q2, net sales increased 8.8% year-over-year to $79.4 million; Med Tech sales grew 13% to $35.7 million At $43.8 million, Med Device sales were up 5.6% in Q2, compared to $41.3 million […]
NYSE
$ANGO · Earnings
“Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026. In Q2, net sales increased 8.8% year-over-year to $79.4 million; Med Tech sales grew 13% to $35.7 million At $43.8 million, Med Device sales were up 5.6% in Q2, compared to $41.3 million […]
· January 6, 2026
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026.
ADVERTISEMENT